[Trial of the clinical use of Ritmilen].
The clinical analysis of the rhythmilene efficacy was performed in 247 patients receiving the drug for various arrhythmias. Due to its anticholinergic properties rhythmilene somewhat increased the sinus rhythm and improved atrioventricular conduction. These properties of the drug often caused urination retention, largely in males over 55 years. The drug was highly active in ventricular paroxysmal tachycardia and extrasystole. The scheme of an interrupted administration of rhythmilene and cordaron for preventing attacks of atrial fibrillation and flutter was worked out. The necessity of the systematic control of the duration of the Q-T interval is emphasized.
D000328:Adult; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004206:Disopyramide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004452:Echocardiography; D004562:Electrocardiography; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012849:Sinoatrial Node / Q000187:drug effects
D000889:Anti-Arrhythmia Agents; D004206:Disopyramide; D000638:Amiodarone
Opyt klinicheskogo primeneniia ritmilena.